Well played. All fair points. Love a good discussion.
A counter to Vyera is that the better quality companies do not want to deal with NP(heard that first hand). I requested some positives and there are some, the loan was another.
To be fair back my way, we really have to search to find positive vindication for NP’s Exectutive prowess.
Should a drug like this not have tip top management?
Is it better to have mediocre management or great management?
This team continues to struggle even accurately filing a 10K.
I loved the blustering CEO comment. I can take and give it alike.
I will stop with kool-aid comments. It was not directed at an individual, merely blind following of the pied piper and IMO there is that, but I will find a kinder gentler ?way to describe it.
On balance, IMO, there is more evidence for dismissal than retention.
The run up from $0.30 to $3.00 was in large part to to HIV...(.he gets credit for that as well as credit for botching everything after that; where are we now on HIV) and the hyperbole associated with CoVID... where are we now on that.
Who was responsible for the run down from $10 to sub $3 close today?
News 
Market Data 
Discover 
AI
